Instructions for Authors
SCOPE & AIM
Annals of Laboratory Medicine (Ann Lab Med; ALM) is the official journal of Korean Society for Laboratory Medicine (KSLM), published bimonthly (every other month from January) in English. The journal publishes Original Articles, Case Reports, Brief Communications, Letters to the Editor, Review, Editorials, Corrections, and Correspondence about new and important subjects in laboratory medicine that are related to the etiology, diagnosis, and treatment of diseases that are scientific, original, ethical, and academically significant.
GENERAL CONSIDERATIONS
The manuscripts should be written in English. Ann Lab Med currently does not accept Case Reports but will consider publication for exceptionally unique and educational cases. Brief Communications are intended for the presentation of brief observations that do not warrant full length papers, but have sufficient originality and utility to be considered for publication. The information must be presented in sufficient detail so that readers can understand and appreciate the material presented. Brief communications undergo the same review process as full-length papers and are not published sooner than the full-length papers. The manuscripts are classified according to the following 8 specific areas, and the author should state the appropriate area of interest in their manuscripts. However, the associate editor of each field may request to the author to change the area of interest and resubmit the manuscript, if necessary.
Specific areas include:
Diagnostic Hematology
Clinical Chemistry
Clinical Microbiology
Diagnostic Immunology
Transfusion Medicine
Diagnostic Genetics
Laboratory Informatics
General Laboratory Medicine
Ethical considerations: For the policies on the research and publication ethics such as plagiarism/duplicate publication/research misconduct, Ann Lab Med adheres to the “Code of Conduct and Best Practice Guidelines for Journal Editors (https://publicationethics.org/resources/code-conduct), previously published as “Guidelines on Good Publication Practice”. Experiments conducted on human subjects should be performed according to the Declaration of Helsinki https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/) and approved by the Research Ethics Committee or the Institutional Review Board (IRB) of the institution where the experiment was performed. Written informed consent should be obtained from all subjects, when necessary. In the case of an animal study, it should be mentioned that the experimental processes such as breeding and the use of laboratory animals were approved by the Research Ethics Committee of the institution where the experiment was performed or that these processes complied with the rules of the Research Ethics Committee of the institution or National Institutes for Health (NIH) Guide for the Care and Use of Laboratory Animals (National Research Council. 2011. Guide for the Care and Use of Laboratory Animals, https://doi.org/10.17226/12910). The authors should retain the raw data of the experiment and study for at least a year after the publication of the paper and should present these data if required by the editorial board.
Clinical Trial Data Sharing Plan: As of July 1, 2018, manuscripts that report the results of clinical trials must contain a data sharing statement that indicates the following:
what data in particular will be shared
whether additional, related documents will be available (e.g. study protocol, statistical analysis plan, etc.)
when the data will become available and for how long
by what access criteria data will be shared (including with whom, for what types of analyses, and by what mechanism)
whether individual deidentified participant data (including data dictionaries) will be shared
Also clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial’s registration. This is an effort of adherence to the ICMJE policy and further information regarding this policy can be found at http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html.
Duplicate Publication: The manuscripts are accepted only on the understanding that they have not been published elsewhere. The manuscripts published in this journal cannot be submitted for publication elsewhere. If the author(s) wishes a duplicate or a secondary publication, for example, for the readers of a different language, the author must obtain approval from the Editor-in-Chief of both the first and second journals. Further, the conditios specified in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals http://www.icmje.org (updated December 2017) should be met, such as insertion of a comment as a footnote in the title page of the second journal stating the primary reference and the duplicate nature of the paper.
Authorship: Only those who have made significant contributions to the preparation and publication of the manuscript are eligible for authorship and should take responsibility for the same. Each author should sign electronically the Authorship Responsibility and Copyright Transfer Agreement Form attesting that he or she fulfills the authorship criteria before or after acceptance for publication. Authors are required to identify their contributions to the work described at the title page of the manuscript.
Disclosure of conflict of interest: Each author is responsible for disclosing to the Publisher all potential conflicts of interest regarding the manuscript and whether the author regards them as actual conflicts of interest. In particular, funding support (grant) information, if applicable, should be provided with both ‘funding agency’ and ‘grand number’. Corresponding author should sign electronically a statement disclosing any conflict of interest on behalf of all author(s) at the time of submission. Each author also should sign electronically a statement disclosing any conflict of interest at the journal website after acceptance of the manuscript.
Personal data and protection of privacy: Information provided during manuscript submission progress will be used for providing services that we offer. ALM is commited to protecting personal data and privacy, and should anyone have concern over this issue, please refer to our privacy policy page. For studies using personal data and any other third-party resources (e.g. social media, webpage and etc.) should be collected and used according to each Terms and Conditions of the source also with appropriate permissions. Please remember to acknowlede those data sources clearly within your manuscript.
……
更多详情：
https://www.annlabmed.org/content/authors/instructions_for_authors.html
